Anti-EGFR Strategy for Colorectal Cancer: Searching for the Real Target

Title: Anti-EGFR Strategy for Colorectal Cancer: Searching for the Real Target

Volume: 3 Issue: 8

Author(s): A. Zaniboni and F. Meriggi

Affiliation:

Keywords: Cetuximab, Colorectal cancer, Anti-EGFR therapy

Abstract: The epidermal growth factor receptor (EGFR) provides survival signals and is overexpressed in the majority of colorectal cancer. Cetuximab is a recombinant human/mouse monoclonal antibody(MoAb) against EGFR, clinically active in the treatment of human colorectal cancer. Unlike the predictable correlation of response to trastuzumab, another MoAb clinically active in a subgroup of breast cancer patients expressing HER-2/neu, responses to cetuximab in EGFR-expressing colorectal cancer is not predictable. The search for a reliable marker that would allow clinicians to select patients for cetuximab therapy remains a major challenge.

Cite this article as:

Zaniboni A. and Meriggi F., Anti-EGFR Strategy for Colorectal Cancer: Searching for the Real Target, Letters in Drug Design & Discovery 2006; 3 (8) . https://dx.doi.org/10.2174/157018006778194673